T Vujic1, Obradovic Nagorni1,2, G Maric3, L Popovic4, J Jankovic1. 1. Clinic for Pulmology, Clinical Centre of Serbia, Belgrade, Serbia. 2. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 3. Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 4. Clinic of Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade, Serbia.
Abstract
BACKGROUND: Metabolic syndrome (MetS) is frequent in patients with chronic obstructive pulmonary disease (COPD). Systemic inflammation plays an important role in both COPD and MetS. The aim of this study was to assess the frequency of MetS in COPD patients and to evaluate the status of systemic inflammation in COPD patients with MetS and those without MetS. METHODS: This cross-sectional study included 98 consecutive stable COPD patients. The MetS was defined using the criteria of the International Diabetes Federation. Components of MetS and markers of systemic inflammation: C-reactive protein (CRP), fibrinogen, and leukocyte count were measured. All patients underwent spirometry. The staging of COPD was made according to the Global initiative for chronic obstructive lung disease (GOLD) criteria. RESULTS: MetS was present in 37.8 % COPD patients. The frequencies of MetS in patients with GOLD stages I, II, III, and IV were 33.3 %, 48.8 %, 31.6 %, and 23.1 %, respectively. MetS frequencies were not significantly different between GOLD stages. The multivariate logistic regression analysis revealed leukocyte count and CRP level as significant independent predictors of the presence of Mets in COPD patients (OR =1.321, 95%CI: 1.007-1.628, p =0.009 and OR =1.184, 95%CI: 1.020-1.376, p =0.027 respectively). CONCLUSIONS: This study shows that MetS is frequent in patients with COPD. Systemic inflammatory markers are higher in COPD patients with MetS than in patients without MetS. These findings suggest that physicians should screen COPD patients for associated MetS and elevated circulatory inflammatory markers. Management of these disorders should reduce the risk of cardiovascular morbidity and mortality in these patients. Hippokratia 2016, 20(2):110-114.
BACKGROUND:Metabolic syndrome (MetS) is frequent in patients with chronic obstructive pulmonary disease (COPD). Systemic inflammation plays an important role in both COPD and MetS. The aim of this study was to assess the frequency of MetS in COPDpatients and to evaluate the status of systemic inflammation in COPDpatients with MetS and those without MetS. METHODS: This cross-sectional study included 98 consecutive stable COPDpatients. The MetS was defined using the criteria of the International Diabetes Federation. Components of MetS and markers of systemic inflammation: C-reactive protein (CRP), fibrinogen, and leukocyte count were measured. All patients underwent spirometry. The staging of COPD was made according to the Global initiative for chronic obstructive lung disease (GOLD) criteria. RESULTS: MetS was present in 37.8 % COPDpatients. The frequencies of MetS in patients with GOLD stages I, II, III, and IV were 33.3 %, 48.8 %, 31.6 %, and 23.1 %, respectively. MetS frequencies were not significantly different between GOLD stages. The multivariate logistic regression analysis revealed leukocyte count and CRP level as significant independent predictors of the presence of Mets in COPDpatients (OR =1.321, 95%CI: 1.007-1.628, p =0.009 and OR =1.184, 95%CI: 1.020-1.376, p =0.027 respectively). CONCLUSIONS: This study shows that MetS is frequent in patients with COPD. Systemic inflammatory markers are higher in COPDpatients with MetS than in patients without MetS. These findings suggest that physicians should screen COPDpatients for associated MetS and elevated circulatory inflammatory markers. Management of these disorders should reduce the risk of cardiovascular morbidity and mortality in these patients. Hippokratia 2016, 20(2):110-114.
Authors: Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella Journal: Hypertension Date: 2004-12-20 Impact factor: 10.190
Authors: K-B H Lam; R E Jordan; C Q Jiang; G N Thomas; M R Miller; W S Zhang; T H Lam; K K Cheng; P Adab Journal: Eur Respir J Date: 2009-07-02 Impact factor: 16.671
Authors: Elena V Kashtanova; Yana V Polonskaya; Evgeniia V Striukova; Liliia V Shcherbakova; Evgenii A Kurtukov; Viktoriya S Shramko; Ekaterina M Stakhneva; Yulia I Ragino Journal: Diagnostics (Basel) Date: 2022-01-25
Authors: Jeizziani Aparecida Ferreira Pinto; Pedro Henrique Batista de Freitas; Fernanda Daniela Dorneles Nunes; Paulo Afonso Granjeiro; Luciana Lara Dos Santos; Richardson Miranda Machado Journal: Rev Lat Am Enfermagem Date: 2018-05-17
Authors: Sangmi S Park; Jessica L Perez Perez; Brais Perez Gandara; Christina W Agudelo; Romy Rodriguez Ortega; Huma Ahmed; Itsaso Garcia-Arcos; Cormac McCarthy; Patrick Geraghty Journal: Medicina (Kaunas) Date: 2022-08-01 Impact factor: 2.948
Authors: Emily A Clementi; Angela Talusan; Sandhya Vaidyanathan; Arul Veerappan; Mena Mikhail; Dean Ostrofsky; George Crowley; James S Kim; Sophia Kwon; Anna Nolan Journal: Toxics Date: 2019-01-30